Patents by Inventor Ulrich Feige
Ulrich Feige has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9534032Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: GrantFiled: April 30, 2014Date of Patent: January 3, 2017Assignee: AMGEN INC.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet C. Cheetham
-
Patent number: 9145450Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: GrantFiled: January 19, 2006Date of Patent: September 29, 2015Assignee: AMGEN INC.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet C. Cheetham
-
Publication number: 20150024431Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: ApplicationFiled: April 30, 2014Publication date: January 22, 2015Applicant: AMGEN INC.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet C. Cheetham
-
Patent number: 8748571Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: GrantFiled: October 20, 2011Date of Patent: June 10, 2014Assignee: Amgen Inc.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet C. Cheetham
-
Patent number: 8618044Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: GrantFiled: April 27, 2012Date of Patent: December 31, 2013Assignee: Amgen Inc.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet C. Cheetham
-
Publication number: 20120208760Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: ApplicationFiled: April 27, 2012Publication date: August 16, 2012Applicant: AMGEN INC.Inventors: Chuan-Fa LIU, Ulrich FEIGE, Janet C. CHEETHAM
-
Publication number: 20120034657Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: ApplicationFiled: October 20, 2011Publication date: February 9, 2012Applicant: AMGEN INC.Inventors: Chuan-Fa LIU, Ulrich FEIGE, Janet C. CHEETHAM
-
Patent number: 8044174Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: GrantFiled: September 2, 2004Date of Patent: October 25, 2011Assignee: Amgen Inc.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet C. Cheetham
-
Patent number: 7994117Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: GrantFiled: March 13, 2009Date of Patent: August 9, 2011Assignee: Amgen Inc.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet C. Cheetham
-
Patent number: 7579316Abstract: Methods and compositions for modulating an immune response to an immunogenic therapeutic agent are disclosed. One of the disclosed methods comprises administering an effective amount of CTLA-4 to decrease the incidence of an immune reaction in conjunction with the administration of a potentially immunogenic substance. Another method contemplates tolerizing a subject to a therapeutic molecule that is or is capable of being immunogenic by the administration of CTLA-4. Various embodiments of CTLA-4 are also disclosed.Type: GrantFiled: February 14, 2005Date of Patent: August 25, 2009Assignee: Amgen Inc.Inventors: Sanjay D. Khare, Ulrich Feige
-
Publication number: 20090186822Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: ApplicationFiled: March 13, 2009Publication date: July 23, 2009Applicant: AMGEN INC.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet C. Cheetham
-
Patent number: 7488590Abstract: Pharmacologically active compounds are prepared by (a) selecting at least one peptide that modulates the activity of AGP-3, (b) preparing a gene construct that comprises at least one said selected sequence, and (c) expressing the pharmacologically active compound in which an Fc domain is covalently linked to the selected peptide. The pharmacologic agent can be expressed in E. coli.Type: GrantFiled: August 18, 2003Date of Patent: February 10, 2009Assignee: Amgen Inc.Inventors: Ulrich Feige, Chuan-Fa Liu, Janet C. Cheetham, Thomas Charles Boone, Jean Marie Gudas
-
Publication number: 20070142295Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: ApplicationFiled: December 22, 2006Publication date: June 21, 2007Applicant: AMGEN INC.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet Cheetham
-
Patent number: 7189827Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.Type: GrantFiled: July 31, 2003Date of Patent: March 13, 2007Assignee: Amgen Inc.Inventor: Ulrich Feige
-
Patent number: 7186810Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.Type: GrantFiled: August 29, 2003Date of Patent: March 6, 2007Assignee: Amgen Inc.Inventor: Ulrich Feige
-
Publication number: 20070049532Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by selecting a peptide that modulates the activity of a protein of interest and preparing a pharmacologic agent having an Fc domain covalently linked to the peptide. Linkage to the Fc domain increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The peptide can be selected, for example, by phage display, E. coli display, ribosome display, RNA-peptide screening, yeast-based screening, chemical-peptide screening, rational design, or protein structural analysis.Type: ApplicationFiled: October 31, 2006Publication date: March 1, 2007Inventors: Ulrich Feige, Chuan-Fa Liu, Janet Cheetham, Thomas Boone
-
Patent number: 7169905Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.Type: GrantFiled: August 29, 2003Date of Patent: January 30, 2007Assignee: Amgen Inc.Inventor: Ulrich Feige
-
Patent number: 7166707Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.Type: GrantFiled: June 27, 2003Date of Patent: January 23, 2007Assignee: Amgen Inc.Inventor: Ulrich Feige
-
Publication number: 20060234307Abstract: The present invention concerns fusion of Fc domains with Ang-2 binding peptides and a process for preparing such molecules. In this invention, pharmacologically active compounds are prepared by a process comprising (a) selecting at least one random peptide that binds to Ang-2; and (b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide can be selected, for example, by phage display, E. coli display, ribosome display, RNA-peptide screening, yeast-based screening, chemical-peptide screening, rational design, or protein structural analysis.Type: ApplicationFiled: June 20, 2006Publication date: October 19, 2006Inventors: Ulrich Feige, Chuan-Fa Liu, Janet Cheetham, Thomas Boone, Jean Gudas
-
Publication number: 20060189531Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: ApplicationFiled: January 19, 2006Publication date: August 24, 2006Applicant: AMGEN INC.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet Cheetham